Literature DB >> 21330034

Impact of comprehensive and intensive treatment of risk factors concerning cardiovascular mortality in secondary prevention: MIRVAS Study.

Miguel A Moreno-Palanco1, Patricia Ibáñez-Sanz, Cristina Ciria-de Pablo, Alberto Pizarro-Portillo, Francisco Rodríguez-Salvanés, Carmen Suárez-Fernández.   

Abstract

INTRODUCTION AND
OBJECTIVES: The aim was to determine whether secondary prevention involving the comprehensive and intensive treatment of cardiovascular risk factors reduces cardiovascular events and cardiovascular mortality at 3-year follow up.
METHODS: The study design comprised a randomized, controlled, open trial in a routine clinical practice setting. In total, 247 patients who presented with acute coronary syndrome or stroke were selected. They were randomized to comprehensive and intensive treatment of cardiovascular risk factors (n=121) or to follow-up based on usual care (n=126). The main study outcomes were the number of cardiovascular events and cardiovascular mortality at 3-year follow-up. The percentage of patients in whom each risk factor was successfully controlled was a secondary outcome.
RESULTS: Overall, 88.8% of patients assigned to the intensive treatment group had a low-density lipoprotein cholesterol level <100mg/dl compared with 56.4% of the usual-care group (relative risk [RR]=1.57; 95% confidence interval [CI], 1.28-1.93), and 75.7% of diabetics had a hemoglobin A(1c) <7% compared with 28.6% of the usual-care group (RR=2.65; 95% CI, 1.13-6.19). There were four deaths due to cardiovascular causes and 26 nonfatal events in the intensive treatment group versus 17 deaths and 54 nonfatal events in the usual-care group. The cumulative survival rate at 3 years was 97.4% in the intervention group and 85.5% in the control group (p=.003).
CONCLUSIONS: Secondary prevention involving comprehensive and intensive treatment of cardiovascular risk factors reduced both morbidity and mortality at 3-year follow up.
Copyright © 2009 Sociedad Española de Cardiología. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21330034     DOI: 10.1016/j.recesp.2010.07.009

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  5 in total

1.  Simplified lipid guidelines: Prevention and management of cardiovascular disease in primary care.

Authors:  G Michael Allan; Adrienne J Lindblad; Ann Comeau; John Coppola; Brianne Hudson; Marco Mannarino; Cindy McMinis; Raj Padwal; Christine Schelstraete; Kelly Zarnke; Scott Garrison; Candra Cotton; Christina Korownyk; James McCormack; Sharon Nickel; Michael R Kolber
Journal:  Can Fam Physician       Date:  2015-10       Impact factor: 3.275

Review 2.  Interventions for improving modifiable risk factor control in the secondary prevention of stroke.

Authors:  Bernadeta Bridgwood; Kate E Lager; Amit K Mistri; Kamlesh Khunti; Andrew D Wilson; Priya Modi
Journal:  Cochrane Database Syst Rev       Date:  2018-05-07

3.  Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease.

Authors:  João Tomé-Carneiro; Manuel Gonzálvez; Mar Larrosa; María J Yáñez-Gascón; Francisco J García-Almagro; José A Ruiz-Ros; Francisco A Tomás-Barberán; María T García-Conesa; Juan Carlos Espín
Journal:  Cardiovasc Drugs Ther       Date:  2013-02       Impact factor: 3.727

4.  Adequacy of control of cardiovascular risk factors in ambulatory patients with type 2 diabetes attending diabetes out-patients clinic at a county hospital, Kenya.

Authors:  Mercy W Kimando; Frederick C F Otieno; Elijah N Ogola; Kenn Mutai
Journal:  BMC Endocr Disord       Date:  2017-12-01       Impact factor: 2.763

5.  Long-term effects on cardiovascular risk of a structured multidisciplinary lifestyle program in clinical practice.

Authors:  Matthias Lidin; Mai-Lis Hellénius; Monica Rydell-Karlsson; Elin Ekblom-Bak
Journal:  BMC Cardiovasc Disord       Date:  2018-04-02       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.